Form 4: Acrivon CFO Adam Levy Buys Shares Under 10b5-1 Plan

Acrivon Therapeutics' Chief Financial Officer, Adam D. Levy, purchased 8,832 shares of common stock at a weighted average price of $1.6983.

Summary

• Adam D. Levy, Chief Financial Officer of Acrivon Therapeutics, Inc. (ACRV), acquired 8,832 shares of the company's common stock.
• The transaction occurred on January 14, 2026.
• The shares were purchased at a weighted average price of $1.6983 per share, with individual trades ranging from $1.695 to $1.7086.
• Following this acquisition, Mr. Levy beneficially owns a total of 20,983 shares of Acrivon Therapeutics common stock.
• The purchase was made pursuant to a Rule 10b5-1(c) plan, which provides an affirmative defense against insider trading allegations.

Sentiment

Score: 7

Explanation: The Chief Financial Officer's purchase of company stock indicates a degree of confidence in the company's prospects, which is generally viewed positively by the market.

Positives

• Chief Financial Officer Adam D. Levy's purchase of 8,832 shares of Acrivon Therapeutics common stock signals management's confidence in the company's future prospects.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned and compliant approach to insider trading.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction reflects an individual executive's investment decision and does not directly provide broader industry context or trends.

Corporate Governance

Related Party Transactions

• Chief Financial Officer Adam D. Levy purchased 8,832 shares of Acrivon Therapeutics common stock from the open market.

Stakeholder Impact

• Shareholders: Insider buying by a key executive can positively influence investor sentiment by signaling management's belief in the company's value and future performance.

Key Dates

Recommendation

The purchase of company stock by the Chief Financial Officer is a positive signal, indicating internal confidence in Acrivon Therapeutics. While this insider buying is a favorable indicator, a single transaction typically warrants a 'hold' recommendation rather than a 'buy' without further comprehensive analysis of the company's financial performance, strategic initiatives, and market position.

Keywords

Acrivon Therapeutics, ACRV, Adam D. Levy, Chief Financial Officer, CFO, Insider Trading, Stock Purchase, Common Stock, Beneficial Ownership, Form 4, Rule 10b5-1